SCHEMBL2643749

SCHEMBL2643749

COCCN(C)C(=O)c1ccc(Oc2cc(C(=O)O)cc3c2CC(C)(C)O3)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 4/20 0.49
LPAR1 Q92633 3/20 0.39
LPAR5 Q9H1C0 3/20 0.39
FFAR4 Q5NUL3 2/20 0.34
RAB9A P51151 1/20 0.33
MTOR P42345 2/20 0.33
PIK3CA P42336 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B10 Q99714 1/20 0.32
EED O75530 1/20 0.32
EZH2 Q15910 1/20 0.32
SCN9A Q15858 1/20 0.31
NAMPT P43490 1/20 0.31
LRRK2 Q5S007 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643802 0.91 GCK (0.48) GCKLPAR1LPAR5FFAR4RAB9A
SCHEMBL644377 0.88 GCK (0.52) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL2643788 0.86 GCK (0.47) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL642324 0.85 GCK (0.71) GCK
SCHEMBL2644110 0.84 GCK (0.54) GCKLPAR1LPAR5FFAR4RAB9A
SCHEMBL2644116 0.84 GCK (0.48) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL2643776 0.84 GCK (0.49) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL2643750 0.84 GCK (0.49) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL2645431 0.82 GCK (0.58) GCKLPAR1LPAR5FFAR4KDM4E
SCHEMBL2644107 0.81 GCK (0.56) GCKLPAR1LPAR5FFAR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885LPAR1 3626/4885LPAR5 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.